These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9809017)

  • 1. Prostate cancer screening.
    Mayo Clin Health Lett; 1998 Nov; 16(11):1-3. PubMed ID: 9809017
    [No Abstract]   [Full Text] [Related]  

  • 2. The long-awaited drop in prostate cancer mortality: what does it mean?
    Levy IG
    Cancer Prev Control; 1998 Aug; 2(4):159. PubMed ID: 10093626
    [No Abstract]   [Full Text] [Related]  

  • 3. Quebec prostate cancer mortality dropped in 1996.
    Meyer F; Moore L; Bairati I; Fradet Y
    Cancer Prev Control; 1998 Aug; 2(4):163-6. PubMed ID: 10093628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
    Barry MJ; Mulley AJ
    J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
    [No Abstract]   [Full Text] [Related]  

  • 5. [Prostate cancer: view of the horizon].
    Dauriac P
    Rev Infirm; 2004 Mar; (99):18-9. PubMed ID: 15124488
    [No Abstract]   [Full Text] [Related]  

  • 6. Screening for prostate cancer.
    Brawley OW; Ankerst DP; Thompson IM
    CA Cancer J Clin; 2009; 59(4):264-73. PubMed ID: 19564245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Why screen for prostate cancer in Finland?].
    Auvinen A; Hakama M; Rannikko S; Stenman UH; Tammela T
    Duodecim; 1996; 112(14):1241-3. PubMed ID: 10596093
    [No Abstract]   [Full Text] [Related]  

  • 8. [Screening for prostatic cancer].
    Pushkar' DIu; Govorov AV; Bormotin AV
    Urologiia; 2003; (1):10-5. PubMed ID: 12621959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Balancing the harms and benefits of early detection of prostate cancer.
    van Leeuwen PJ; Connolly D; Tammela TL; Auvinen A; Kranse R; Roobol MJ; Schroder FH; Gavin A
    Cancer; 2010 Oct; 116(20):4857-65. PubMed ID: 20839233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining increased future risk for prostate cancer: evidence from a population based screening cohort.
    Schröder FH; Roobol MJ; Andriole GL; Fleshner N
    J Urol; 2009 Jan; 181(1):69-74; discussion 74. PubMed ID: 19012915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the value of screening for prostate cancer in the US?
    Albertsen PC
    Nat Clin Pract Oncol; 2005 Nov; 2(11):536-7. PubMed ID: 16270077
    [No Abstract]   [Full Text] [Related]  

  • 12. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
    Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upcoming evidences on prostate-specific antigen-based screening for men at risk of prostate cancer.
    Boscolo-Berto R
    Int J Urol; 2009 Sep; 16(9):711. PubMed ID: 19769655
    [No Abstract]   [Full Text] [Related]  

  • 14. Prostate cancer and prostate-specific antigen: facts, figures and commentary.
    Chambers DC
    J Insur Med; 1993; 25(3):336-40. PubMed ID: 10146433
    [No Abstract]   [Full Text] [Related]  

  • 15. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
    Roobol MJ; Grenabo A; Schröder FH; Hugosson J
    J Natl Cancer Inst; 2007 Sep; 99(17):1296-303. PubMed ID: 17728218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-systematic screening for prostate cancer in Sweden--survey from the National Prostate Cancer Registry.
    Stattin P; Johansson R; Damber JE; Hellström M; Hugosson J; Lundgren R; Varenhorst E; Johansson JE
    Scand J Urol Nephrol; 2003; 37(6):461-5. PubMed ID: 14675917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mass screening for prostate cancer is the best approach to early diagnosis and treatment of prostate cancer].
    Zhao XJ; Kong XB; Wang WH
    Zhonghua Nan Ke Xue; 2003 Nov; 9(8):563-5, 568. PubMed ID: 14689882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for prostate cancer.
    Ruffin MT
    J Fam Pract; 1999 Aug; 48(8):581-2. PubMed ID: 10496634
    [No Abstract]   [Full Text] [Related]  

  • 20. Prostate cancer mortality rates compared to urologist population densities and prostate-specific antigen screening levels on a state-by-state basis in the United States of America.
    Colli JL; Amling CL
    Prostate Cancer Prostatic Dis; 2008; 11(3):247-51. PubMed ID: 18268527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.